Add listing
    0
    Add listing

    Vir Biotechnology: Intent to collaborate with Biogen on manufacturing of antibodies to potentially treat Coronavirus

    • Thursday, March 12, 2020 @ 6:00 pm

    Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has signed a letter of intent with Biogen Inc. (Nasdaq: BIIB) for the development and clinical manufacturing of human monoclonal antibodies for the potential treatment of COVID-19, the disease caused by the SARS-CoV-2 virus. Because of the urgency of the situation, the companies have begun work while a Clinical Development and Manufacturing Agreement is being negotiated.

    Subject to the completion of a definitive agreement, Biogen would continue cell line development, process development, and clinical manufacturing activities in order to advance the development of Vir’s proprietary antibodies.“These exceptional circumstances presented by the threat of COVID-19 require that we work with great urgency in the interest of the public good,” said George Scangos, Ph.D., CEO, Vir. “Biogen is one of the global leaders in cell line and process development for advanced biologics; tapping into their capabilities will provide us with a U.S. base for supply and manufacture of antibody therapies.

    ”Vir has identified a number of monoclonal antibodies that bind to SARS-CoV-2, which were isolated from individuals who had survived a SARS (Severe Acute Respiratory Syndrome) infection. The company is conducting research to determine if its antibodies, or additional antibodies that it may be able to identify, can be effective as treatment and/or prophylaxis against SARS-CoV-2.

    You may also be interested in